This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tenet Healthcare (THC) to Buy 45 Ambulatory Surgery Centers
by Zacks Equity Research
Tenet Healthcare (THC) to purchase 45 ambulatory surgery centers to aid its USPI ambulatory business, thus bolstering its position as a national musculoskeletal services leader in healthcare.
Is Tenet Healthcare (THC) a Profitable Stock to Pick Now?
by Zacks Equity Research
Is Tenet Healthcare (THC) a great pick from the value investor's perspective right now? Read on to know more.
Why Is Tenet (THC) Up 11.8% Since Last Earnings Report?
by Zacks Equity Research
Tenet (THC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Community Health (CYH) Soars 168.6% YTD: More Room to Run?
by Zacks Equity Research
Community Health's (CYH) strategic measures along with the surge in telehealth visits are likely to fetch revenues, which in turn, may bump up its share price.
MEDNAX's (MD) Q3 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
MEDNAX's (MD) third-quarter results reflect muted revenues and high costs, partly offset by lower interest expense.
Teladoc (TDOC) Q3 Earnings Beat Estimates, Hikes '20 Guidance
by Zacks Equity Research
Teladoc's (TDOC) third-quarter results reflect robust revenues and solid uptick in patient visits, partially offset by elevated costs.
Acadia Healthcare's (ACHC) Shares Up on Q3 Earnings Beat
by Zacks Equity Research
Acadia Healthcare's (ACHC) shares gain on third-quarter earnings beat, which has been driven by higher revenues. However, elevated costs have partially offset the results.
HCA Healthcare (HCA) Q3 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results reflect decline in admissions, partly offset by higher revenues.
Tenet Healthcare's (THC) Earnings Beat in Q3, Improve Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) third-quarter earnings gain from the Ambulatory segment and lower expenses.
Tenet Healthcare (THC) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 93.94% and 4.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Tenet Healthcare (THC) Stock
by Zacks Equity Research
Riding high on its strategic measures and cost-cutting methods, Tenet Healthcare (THC) holds enough potential to reap benefits for yield-seeking investors.
Analysts Estimate Tenet Healthcare (THC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Tenet (THC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HCA Healthcare (HCA) Announces Preliminary Results for Q3
by Zacks Equity Research
HCA Healthcare (HCA) reports preliminary results for the third quarter of 2020. Final results will be released on or around Oct 26.
Here's Why You Should Stay Away From HCA Healthcare Now
by Zacks Equity Research
HCA Healthcare (HCA) business is persistently hurt by the adverse coronavirus impact, which makes it an unattractive bet.
Zacks Industry Outlook Highlights: HCA, UHS, ACHC and THC
by Zacks Equity Research
Zacks Industry Outlook Highlights: HCA, UHS, ACHC and THC
Acadia Healthcare Offers Senior Unsecured Notes for $475M
by Zacks Equity Research
Acadia Healthcare (ACHC) exhibits sharp business acumen by issuing senior notes to procure funds.
4 Hospital Stocks to Gain from Improving Admissions, Federal Aid
by Sapna Bagaria
Federal relief, higher admissions and cost containment are likely to aid the Zacks Medical-Hospital industry. HCA, UHS, CYH and THC are well-positioned to gain from a revival in admissions.
Zacks Industry Outlook Highlights: CYH, HCA, UHS and THC
by Zacks Equity Research
Zacks Industry Outlook Highlights: CYH, HCA, UHS and THC
Centene (CNC) Offers Senior Unsecured Notes Valued $2.2B
by Zacks Equity Research
Centene (CNC) exhibits prudence by issuing senior notes amid a low interest rate environment to procure funds.
UHS or THC: Which is a Better-Positioned Stock Right Now?
by Zacks Equity Research
Universal Health (UHS) and Tenet Healthcare (THC) are poised to grow. On comparative evaluation, we try to discover which is a more profitable bet based on the fundamentals.
What Makes Select Medical (SEM) an Attractive Investment Pick
by Zacks Equity Research
Solid operating fundamentals and rising earnings estimate make Select Medical (SEM) a lucrative stock.
MEDNAX Divests Radiology Business to Focus on Core Operations
by Zacks Equity Research
MEDNAX (MD) reaches an agreement with Radiology Partners to sell its MEDNAX Radiology Solutions, which will lower its debt load and restructure its business.
Why Should You Hold on to Tenet Healthcare (THC) Stock?
by Zacks Equity Research
Riding high on divestitures and cost-reduction, Tenet Healthcare (THC) holds enough potential to reap benefits for yield-seeking investors.
Acadia Healthcare, Covenant Health to Offer Mental Healthcare
by Zacks Equity Research
Acadia Healthcare (ACHC) and Covenant Health to unveil East Tennessee Behavioral Health to cater to the mental care services of communities in and around Knoxville.
Tenet Healthcare Offers Senior Unsecured Notes Worth $2.5B
by Zacks Equity Research
Tenet Healthcare (THC) exhibits prudence by issuing senior notes amid a low interest rate environment to procure funds.